Compare MGM Resorts International (MGM) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Novo Nordisk A/S — how do they compare? MGM Resorts International trades at $45.92 (market cap $11.86B), while Novo Nordisk A/S trades at $49.33 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 18.6× MGM Resorts International's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| MGM | NVO | |
|---|---|---|
Market Cap | $11.86B | $220.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $71.70 |
52-Week Low | $30.72 | $35.29 |
Enterprise Value | $40.90B | $239.49B |
Dividend Yield | 0.03% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $46.55, up 0.91% today, amid ongoing acquisition talks with Barry Diller's People Inc. at $48.30 per share. The stock shows mixed technical signals with a bullish moving average trend but neutral oscillators. Fundamentally, revenue grew to $17.54B in 2025, though net income margin compressed to 1.03%. Analyst consensus is evenly split between Buy and Hold, with a $48.93 price target suggesting modest upside from current levels.
MGM's outlook is clouded by acquisition uncertainty and declining profitability, offset by potential takeover premium and stable revenue. Key risks include execution on margin improvement, high debt levels, and macroeconomic sensitivity. The stock presents a speculative opportunity tied to deal completion, with fundamental challenges requiring careful monitoring.
Novo Nordisk (NVO) trades at $49.68, down 1.27% on the day, amid a bullish technical signal from moving averages. The company demonstrates robust fundamentals with a trailing P/E of 12.08 and a net income margin of 37.2%, supported by three consecutive quarterly earnings beats. Recent positive catalysts include EU and Indian regulatory approvals for its oral Wegovy weight-loss pill, expanding its GLP-1 franchise.
The outlook remains positive given strong analyst consensus (57.9% Buy ratings) and projected earnings growth, though risks include intensifying competition in the weight-loss drug market and potential margin pressure. The stock presents a compelling opportunity for investors seeking exposure to a profitable leader in metabolic diseases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
